Teva Pharmaceutical Industries Ltd. $TEVA Holdings Lowered by Phoenix Financial Ltd.

Phoenix Financial Ltd. lowered its position in Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) by 0.5% during the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 41,087,131 shares of the company’s stock after selling 208,113 shares during the period. Teva Pharmaceutical Industries makes up about 13.7% of Phoenix Financial Ltd.’s investment portfolio, making the stock its biggest position. Phoenix Financial Ltd.’s holdings in Teva Pharmaceutical Industries were worth $1,282,329,000 at the end of the most recent reporting period.

Several other hedge funds have also recently bought and sold shares of TEVA. Harel Insurance Investments & Financial Services Ltd. raised its holdings in Teva Pharmaceutical Industries by 19.2% during the fourth quarter. Harel Insurance Investments & Financial Services Ltd. now owns 44,951,773 shares of the company’s stock worth $1,402,945,000 after purchasing an additional 7,255,083 shares during the last quarter. Wellington Management Group LLP grew its holdings in Teva Pharmaceutical Industries by 39,228.4% in the third quarter. Wellington Management Group LLP now owns 6,895,838 shares of the company’s stock valued at $139,296,000 after purchasing an additional 6,878,304 shares during the last quarter. Farallon Capital Management LLC purchased a new position in shares of Teva Pharmaceutical Industries in the third quarter valued at $100,939,000. Migdal Insurance & Financial Holdings Ltd. raised its stake in shares of Teva Pharmaceutical Industries by 14.8% during the 4th quarter. Migdal Insurance & Financial Holdings Ltd. now owns 37,402,212 shares of the company’s stock worth $1,167,323,000 after buying an additional 4,820,000 shares during the last quarter. Finally, Bessemer Group Inc. raised its stake in shares of Teva Pharmaceutical Industries by 861,152.5% during the 4th quarter. Bessemer Group Inc. now owns 4,280,425 shares of the company’s stock worth $133,592,000 after buying an additional 4,279,928 shares during the last quarter. 54.05% of the stock is owned by hedge funds and other institutional investors.

Insiders Place Their Bets

In other news, EVP Eliyahu Sharon Kalif sold 345,810 shares of Teva Pharmaceutical Industries stock in a transaction on Thursday, February 26th. The stock was sold at an average price of $33.64, for a total value of $11,633,048.40. Following the completion of the sale, the executive vice president owned 57,478 shares of the company’s stock, valued at $1,933,559.92. The trade was a 85.75% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, insider Mark Sabag sold 144,180 shares of the stock in a transaction dated Friday, May 1st. The stock was sold at an average price of $34.99, for a total value of $5,044,858.20. Following the transaction, the insider owned 80,760 shares in the company, valued at $2,825,792.40. This trade represents a 64.10% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Over the last quarter, insiders have sold 1,127,018 shares of company stock valued at $37,298,712. 0.54% of the stock is currently owned by insiders.

Analyst Upgrades and Downgrades

A number of equities research analysts recently commented on TEVA shares. The Goldman Sachs Group increased their price objective on shares of Teva Pharmaceutical Industries from $36.00 to $45.00 and gave the company a “buy” rating in a research note on Monday, February 9th. Weiss Ratings restated a “sell (d-)” rating on shares of Teva Pharmaceutical Industries in a research report on Monday, April 20th. Wall Street Zen downgraded shares of Teva Pharmaceutical Industries from a “strong-buy” rating to a “hold” rating in a report on Saturday, May 2nd. Bank of America increased their price target on shares of Teva Pharmaceutical Industries from $38.00 to $42.00 and gave the company a “buy” rating in a research report on Thursday, April 9th. Finally, Barclays raised their price objective on shares of Teva Pharmaceutical Industries from $38.00 to $40.00 and gave the stock an “overweight” rating in a research note on Wednesday, May 6th. Nine investment analysts have rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average target price of $41.78.

Teva Pharmaceutical Industries Stock Down 2.5%

TEVA opened at $35.33 on Friday. The firm has a market cap of $40.62 billion, a P/E ratio of 26.56, a PEG ratio of 3.51 and a beta of 0.86. The business’s fifty day simple moving average is $31.51 and its 200 day simple moving average is $30.40. Teva Pharmaceutical Industries Ltd. has a 52 week low of $14.99 and a 52 week high of $37.35. The company has a quick ratio of 0.78, a current ratio of 1.01 and a debt-to-equity ratio of 1.70.

Teva Pharmaceutical Industries (NYSE:TEVA) last released its earnings results on Tuesday, March 31st. The company reported $0.53 earnings per share (EPS) for the quarter. Teva Pharmaceutical Industries had a net margin of 9.01% and a return on equity of 43.53%. The company had revenue of $3.98 billion for the quarter. As a group, equities research analysts anticipate that Teva Pharmaceutical Industries Ltd. will post 2.49 EPS for the current fiscal year.

About Teva Pharmaceutical Industries

Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) is an Israeli multinational pharmaceutical company and one of the world’s largest manufacturers of generic medicines. The company’s core activities include the development, production and marketing of generic pharmaceuticals alongside a portfolio of specialty branded medicines. Teva supplies finished dosage forms and active pharmaceutical ingredients (APIs) to markets around the globe and operates manufacturing and research facilities in multiple countries.

Teva’s product range covers oral solids, injectables, inhalation products and other dosage forms across therapeutic areas such as central nervous system disorders, respiratory, oncology, pain and infectious disease.